InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $2.040 0.02 (0.97%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$396 Racure Oncology Techknow Invest Presentation 29 Jul 2026 9:12AM $2.040 $2.020 fallen by 0.98%
$396 First HARNESS-1 Patient Safely Treated with RC220 29 Jul 2026 9:04AM $2.040 $2.020 fallen by 0.98%
$396 June 2026 Quarterly Activities Report and Appendix 4C 28 Jul 2026 9:12AM $2.070 $2.020 fallen by 2.42%
$396 Notification of cessation of securities - RAC 13 Jul 2026 8:57AM $2.190 $2.020 fallen by 7.76%
$396 Racura to Present CPACS Data at GCOS 2026 9 Jul 2026 10:42AM $2.130 $2.020 fallen by 5.16%
$396 Racura Oncology New Zealand Investor Events 6 Jul 2026 12:38PM $2.250 $2.020 fallen by 10.22%
$396 Bellberry Ethics Approval Activates New HARNESS Trial Sites 3 Jul 2026 8:46AM $2.280 $2.020 fallen by 11.40%
$396 Notification of cessation of securities - RAC 2 Jul 2026 8:29AM $2.200 $2.020 fallen by 8.18%
$396 Racura Treats First Patient in HARNESS-1 Lung Cancer Trial 25 Jun 2026 8:55AM $2.310 $2.020 fallen by 12.55%
$396 Racura Oncology Investor Briefings Perth & Auckland 16 Jun 2026 12:54PM $2.560 $2.020 fallen by 21.09%
$396 Racura raised $34.3m to Advance Three Oncology Trials 16 Jun 2026 12:36PM $2.320 $2.020 fallen by 12.93%
$396 Cleansing Notice 16 Jun 2026 12:33PM $2.320 $2.020 fallen by 12.93%
$396 Application for quotation of securities - RAC 16 Jun 2026 12:27PM $2.320 $2.020 fallen by 12.93%
$396 Cleansing Notice 11 Jun 2026 2:50PM $2.370 $2.020 fallen by 14.77%
$396 Application for quotation of securities - RAC 11 Jun 2026 2:49PM $2.310 $2.020 fallen by 12.55%
$396 Appendix 3Y-Dr Serge Scrofani 9 Jun 2026 8:48AM $2.700 $2.020 fallen by 25.19%
$396 Racura Options Raised $24.4m 4 Jun 2026 12:02PM $2.660 $2.020 fallen by 24.06%
$396 Notification of cessation of securities - RAC 4 Jun 2026 11:57AM $2.530 $2.020 fallen by 20.16%
$396 Proposed issue of securities - RAC 4 Jun 2026 8:52AM $2.510 $2.020 fallen by 19.52%
$396 Emerging Companies Specialist Invests in Racura 4 Jun 2026 8:50AM $2.510 $2.020 fallen by 19.52%
$396 Application for quotation of securities - RAC 1 Jun 2026 3:40PM $2.670 $2.020 fallen by 24.34%
$396 Application for quotation of securities - RAC 29 May 2026 2:50PM $2.530 $2.020 fallen by 20.16%
$396 Proposed issue of securities - RAC 28 May 2026 4:43PM $2.530 $2.020 fallen by 20.16%
$396 Racura Enters Underwriting Agreement for Options 28 May 2026 4:43PM $2.530 $2.020 fallen by 20.16%
$396 Appendix 3Y - Dr Daniel Tillett 28 May 2026 12:12PM $2.640 $2.020 fallen by 23.48%

1 - 25 of 988 results

Page 1 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.